Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer

NCT01142388 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01142388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01142388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 21, 2010
Completion date
March 31, 2027
Enrollment
94 (actual)
Sites
232

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic esophageal adenocarcinoma, metastatic esophageal squamous cell carcinoma, metastatic gastroesophageal junction adenocarcinoma, recurrent esophageal adenocarcinoma, recurrent esophageal carcinoma, recurrent esophageal squamous cell carcinoma, recurrent gastroesophageal junction adenocarcinoma, stage iv esophageal cancer ajcc v7